The stock value of Genprex, Inc. (NASDAQ: GNPX) increasing significantly when it was revealed that it will be attending a prominent European event. As of the last check, GNPX shares soared 16.04% to $2.34.
Following Genprex’s announcement that its management will be attending the forthcoming BIO Europe Conference, which is set for November 4-6, 2024, in Stockholm, Sweden, with a virtual extension on November 12-13, 2024, this expansion follows.
Genprex to Participate in BIO Europe Conference
At the BIO Europe Conference, Genprex plans to make its presence felt both in person and virtually. Thomas Gallagher, Esq., Senior Vice President of Intellectual Property and Licensing, will attend on-site in Stockholm.
Meanwhile, President and CEO Ryan Confer and Chief Medical Officer Dr. Mark Berger will engage virtually, facilitating discussions with industry stakeholders and investors. This participation allows GNPX to share insights into its innovative gene therapies targeting cancer and diabetes.
In order to strengthen relationships with investors and the industry, GNPX also plans to hold one-on-one meetings where it will promote its continuous efforts and developments in healthcare technology.
Promising Preclinical Data At the International Symposium
Genprex’s research partners recently presented encouraging results at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, in addition to their involvement in BIO Europe.
Presentations centered on preclinical results from REQORSA Gene Therapy, Genprex’s flagship therapeutic candidate that targets difficult tumors such glioblastoma, mesothelioma, and Ras inhibitor-resistant lung cancer.
These presentations emphasized REQORSA’s importance in addressing unmet patient needs by highlighting its potential to treat challenging-to-manage malignancies, such as KRAS G12C mutant lung cancer.
GNPX Advancing Patent Applications and Collaborations
Building on these promising developments, Genprex filed two provisional patent applications. These patents cover REQORSA’s applications in treating mesothelioma and glioblastoma, further reinforcing the company’s innovative approach in gene therapy.
These patents are jointly owned by the company and affiliated research institutes, demonstrating the collaboration between business and academic research. GNPX also recently formed a Mesothelioma Clinical Advisory Board, bringing together four distinguished academics from top universities to strengthen its focus on mesothelioma.